TheraRadar
← Back
Data updated: Mar 29, 2026

FERRING

OncologyGastroenterologyImmunology
Biotech

FERRING is a biotechnology company focused on Oncology, Gastroenterology, Immunology.

1974
Since
16
Drugs
-
Trials
6
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

DESMOPRESSIN ACETATE 2025-08-27
Manufacturing (CMC)
ZOMACTON 2025-07-09
Labeling
DESMOPRESSIN ACETATE 2025-04-24
Labeling
DESMOPRESSIN ACETATE 2025-03-21
Labeling
DESMOPRESSIN ACETATE 2024-08-28
Labeling
ZOMACTON 2024-04-02
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 46%
1 drugs Phase 3: 6 Phase 1: 4
Gastroenterology 24%
0 drugs Phase 3: 4 Phase 1: 2
Immunology 23%
0 drugs Phase 3: 4 Phase 1: 1
Infectious Disease 5%
0 drugs Phase 3: 1
Cardiovascular 1%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Gastroenterology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Immunology
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Cardiovascular
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease
COSETTE other
Cardiovascular, Infectious Disease, Immunology, Oncology